Weekly Cladribine Followed by Rituximab for the Treatment of Hairy Cell Leukemia
{{output}}
Introduction: Hairy cell leukemia (HCL) is an uncommon hematopoietic stem cell disease known to have an underlying somatic BRAFV600E driver mutation. Currently, the most accepted treatment is five or seven consecutive days of out... ...